glp-1 law firm Agenda glp1 #pharma | Groom Law

PS-IPW analysis showed no significant differences in BP outcomes or target achievement rates according to the preceding treatment

Initially studied for its role in controlling blood sugar in type 2 diabetes, GLP-1 has now gained attention for its remarkable effects on weight management

GLP-1 Market Enters New Phase The GLP-1 sector continues to evolve rapidly as pharmaceutical developers expand treatment options for obesity, diabetes and related metabolic conditions

Interestingly, W-24 (106), a non-peptide GLP-1RA, has been reported to inhibit inflammatory pain by stimulating the spinal cord GLP-1R for the release of analgesic -endorphin

Several SURMOUNT studies in patients with obesity are ongoing ( In the SURPASS-1 study, which enrolled 705 non-target T2DM patients with diet and physical activity intervention, the efficacy, safety, and tolerability of tirzepatide and a placebo were compared